8-K: Sigyn Therapeutics Converts Debt to Equity, Extends Maturity on Remaining Debentures

Sigyn Therapeutics converted a significant portion of its convertible debentures into Series B Preferred Stock and extended the maturity dates on the remaining debentures.

Summary

• Sigyn Therapeutics converted $220,420 in debentures held by Brio Capital Master Fund Ltd. into 292.4 shares of Series B Preferred Stock on April 9, 2024.
• Additionally, $621,000 in debentures held by Osher Capital Partners, LLC were converted into 823.86 shares of Series B Preferred Stock on April 10, 2024.
• Each share of Series B Preferred Stock is convertible into 125.63 shares of common stock, subject to certain adjustments.
• Brio and Osher also agreed to amend an additional $110,000 and $275,000 of debentures, respectively, extending their maturity to March 31, 2025.
• In return for the extension, the principal amount of these debentures increased to $125,000 and $316,350, respectively.
• A total of $1,856,566 in debentures held by Brio and Osher will automatically convert into Series B Preferred Stock upon the listing of the common stock on NASDAQ.

Sentiment

Score: 6

Explanation: The document indicates a positive step in managing debt, but also highlights potential dilution and increased future obligations. The sentiment is neutral to slightly positive.

Positives

• The conversion of debentures into preferred stock reduces the company's debt burden.
• Extending the maturity of the remaining debentures provides the company with more time to manage its liabilities.
• The automatic conversion of a significant amount of debentures upon NASDAQ listing could be a positive catalyst for the company's stock.

Negatives

• The increase in the principal amount of the extended debentures increases the company's future debt obligations.
• The conversion of debentures into preferred stock dilutes the ownership of existing shareholders.

Risks

• The company's ability to list on NASDAQ is not guaranteed.
• The conversion of debentures into preferred stock could further dilute existing shareholders if the company does not perform well.
• The increased principal amount of the extended debentures could pose a challenge if the company does not generate sufficient cash flow.

Future Outlook

The company anticipates the automatic conversion of $1,856,566 in debentures into Series B Preferred Stock upon the listing of its common stock on NASDAQ.

Management Comments

• James A. Joyce, Chairman and CEO, signed the report on behalf of Sigyn Therapeutics, Inc.

Industry Context

This type of debt conversion and maturity extension is common for companies seeking to improve their balance sheet and prepare for a potential public listing. It is a way to reduce immediate debt obligations and align investor interests with the company's long-term success.

Comparison to Industry Standards

• Many biotech companies use convertible debt as a form of financing, especially in early stages.
• The conversion of debt to equity is a common strategy to reduce leverage and improve financial stability.
• Extending debt maturities is a typical approach to manage cash flow and avoid immediate repayment pressures.
• The specific terms of the conversion and extension, such as the conversion ratio and interest rates, would need to be compared to similar transactions in the biotech industry to assess their favorability.

Stakeholder Impact

• Shareholders may experience dilution due to the conversion of debentures into preferred stock.
• Creditors holding the extended debentures will have a longer repayment period.
• The company's potential NASDAQ listing could positively impact all stakeholders.

Next Steps

• The company will proceed with the automatic conversion of debentures upon NASDAQ listing.
• The company will manage the extended debentures until their maturity date of March 31, 2025.

Key Dates

Keywords

convertible debentures, Series B Preferred Stock, debt conversion, maturity extension, NASDAQ listing, Brio Capital, Osher Capital, equity financing